

Alaska Medicaid

MARINOL®(DRONABINOL)

Available 2.5mg, 5mg and 10mg capsules, Schedule III controlled substance

INDICATIONS and USAGE:

“MARINOL Capsules is indicated for the treatment of:

1. anorexia associated with weight loss in patients with AIDS; and
2. nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.”¹

Criteria for Approval:

For anorexia or nausea associated with weight loss in patients with AIDS

- Must have a documented trial and failure/intolerant of megestrol acetate suspension
 - a. Submit documentation/chart notes

For the treatment of nausea and vomiting associated with cancer

- Must have documented trial and failure/intolerant to at least one previous antiemetic therapies, including a serotonin 5HT₃ antagonist, antihistamine, corticosteroid, prokinetic, or phenothiazine
 - a. Submit dates of each therapy, notes for discontinuation/treatment failure and current schedule of chemotherapy

Length of Authorization:

For anorexia associated with weight loss in patients with AIDS

- Coverage may be approved for up to 6 months

For the treatment of nausea and vomiting associated with cancer chemotherapy

- Coverage may be approved for up to 6 months

Dispensing Limit:

For anorexia associated with weight loss in patients with AIDS

- The dispensing limit is a 30 day supply of medication with a **Quantity Limit** of 2 doses per day

For the treatment of nausea and vomiting associated with cancer chemotherapy

- The dispensing limit is a 30 day supply of medication per chemotherapy cycle

References:

¹ Marinol® package insert is available at:

<<http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=48704>>

Accessed 8/15/12

Marinol criteria

Version 1

Last updated 3/15/2013

Approved 3/15/2013